362703-30-8

Basic information

• Product Name: methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate
• Synonyms: methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate;Methyl 4-Cyanotetrahydro-2H-Pyran-4-Carboxylate(WXC00765);methyl 4-cyanooxane-4-carboxylate
• CAS NO: 362703-30-8
• Molecular Formula: C₈H₁₁NO₃
• Molecular Weight: 169.17784
• Mol File: 362703-30-8.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate(362703-30-8)
• EPA Substance Registry System: methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate(362703-30-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 362703-30-8(Hazardous Substances Data)

Usage

General Description

Methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate is a chemical compound with the molecular formula C8H11NO3. It is a colorless liquid with a strong, fruity odor, and it is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. Methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate is a versatile building block in organic chemistry, often used in the production of various drugs and other organic compounds. It is also used in the manufacturing of perfumes, flavors, and other chemical products due to its unique properties and reactivity. methyl 4-cyanotetrahydro-2H-pyran-4-carboxylate is an important chemical in the field of organic synthesis and is widely utilized in various industries for the production of a wide range of products.

Upstream product

• 111-44-4 3-oxa-1,5-dichloropentane 
• 105-34-0 methyl 2-cyanoacetate 
• 5414-19-7 1,1'-oxybis(2-bromo-ethane) 

Downstream Products

• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 1257044-40-8 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide 
• 130290-79-8 4-tetrahydropyranmethylamine 
• 1228779-96-1 3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide 
• 848821-06-7 4-cyanotetrahydro-2H-pyran-4-carboxylic acid 
• 1010836-56-2 4-(hydroxymethyl)-tetrahydro-2H-pyran-4-carbonitrile 
• 362703-32-0 4-{[4-(2-methyl-quinolin-4-ylmethoxy)-benzoylamino]-methyl}-tetrahydro-pyran-4-carboxylic acid methyl ester 

Relevant articles and documents

NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9

The present invention relates to an inhibitor of cyclin-dependent kinase CDK9, having a structure of formula (I). The present invention also provides a method of treating a cancer of a precancerous condition related to CDK9 activity with the inhibitor and a use of the same.

Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor

Through a structure-guided rational drug design approach, we have discovered a highly selective inhibitor compound 40 (JSH-150), which exhibited an IC50 of 1 nM against CDK9 kinase in the biochemical assay and achieved around 300–10000-fold selectivity over other CDK kinase family members. In addition, it also displayed high selectivity over other 468 kinases/mutants (KINOMEscan S score(1) = 0.01). Compound 40 displayed potent antiproliferative effects against melanoma, neuroblastoma, hepatoma, colon cancer, lung cancer as well as leukemia cell lines. It could dose-dependently inhibit the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrest the cell cycle and induce the apoptosis in the leukemia cells. In the MV4-11 cell-inoculated xenograft mouse model, 10 mg/kg dosage of 40 could almost completely suppress the tumor progression. The high selectivity and good in vivo PK/PD profile suggested that 40 would be a good pharmacological tool to study CDK9-mediated physiology and pathology as well as a potential drug candidate for leukemia and other cancers.

3-(AMINOARYL)-PYRIDINE COMPOUNDS

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.